PCI-34051
PCI-34051 is a potent and selective HDAC8 inhibitor with IC50 of 10 nM, with >200-fold selectivity over the other HDAC isoforms.
Product Specifications
CAS Number
950762-95-5
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; HDAC
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PCI-34051.html
Purity
99.84
Solubility
DMSO : ≥ 30 mg/mL
Smiles
COC(C=C1)=CC=C1CN2C3=CC(C(NO)=O)=CC=C3C=C2
Molecular Formula
C17H16N2O3
Molecular Weight
296.32
Precautions
H302, H315, H319, H335
References & Citations
[1]Balasubramanian S, et al. A novel histone deacetylase 8 (HDAC8) -specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008 May;22 (5) :1026-34.|[2]Ren Y, et al. Therapeutic effects of histone deacetylase inhibitors in a murine asthma model. Inflamm Res. 2016 Dec;65 (12) :995-1008.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC1; HDAC10; HDAC6; HDAC8
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-E678855-250MG 250 mg
5-(N-Ethyl-N-2-hydroxyethylamino)-2-penthlamine
Sign In for Pricing
View Details 
BNC681736-500 1x 500 µL
Glycophorin A / CD235a (Erythrocyte Marker) (N/A), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 